Introduction {#Sec1}
============

Coronaviruses (CoVs) are a family of viruses which were known to cause mild flu like symptoms in humans previously. However, these viruses harboured in wild mammals when transmitted to humans resulted in two pandemics of severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS) during the last two decades. The outbreak of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), popularly known as coronavirus disease 19 (COVID19) is the reoccurrence of infection by SARS related viruses which has been declared by the World Health Organisation (WHO) as a global pandemic. The outbreak occurred in a local sea food market in Wuhan, Hubei province in central China from a probable bat origin (Zhou [@CR29]) which had a human to human transmission to more than 150 countries resulting in severe morbidity and mortality. The check of human to human transmission is only possible at present by following a set of hygienic principles, social distancing, isolation and quarantine of suspected patients as there are no validated therapeutics or a vaccine for prevention of the disease. Inoculation of SARS-CoV-2 in experimental animal reveal susceptibility of infection in cats, ferrets, dogs, hamsters, mouse and NHPs. The research revealing infectivity, pathogenicity and virulence of emerging infectious disease of SARS-CoV and SARS-CoV-2 on experimental animals for development of drugs, identification of therapeutic targets, vaccine trials etc. are gaining momentum. Here, we review some similarity and differences with animal models of SARS-CoV and SARS-CoV-2 infections as both the virus shares a homogeneity in infection pattern, pathogenicity, transmission and ACE2 receptor binding domains of spike protein.

Threats arising out of SARS-L-CoV outbreaks {#Sec2}
===========================================

Coronaviruses capable of infecting humans have been reported as early as 1890s causing flu like symptoms. Prior to outbreak of COVID-19, six CoV strains affecting humans have been reported most of which are harbored in bats and some in rodents (Cui [@CR5]) (Table [1](#Tab1){ref-type="table"}). The outbreak of SARS in 2002 exhibited the ability of CoVs to cause widespread pandemic in human population, however the outbreaks were contained within a span of two years. Initially the palm civets were thought to be the reservoir host of this deadly virus, however when civets were inoculated with field isolates of human SARS-CoV rendered them infected indicating that civets are not the natural host of these CoVs (Wu [@CR28]). Sample survey of 408 bats in 2004 from multiple species, genera and families in different provinces of China indicated a widespread seropositivity of SARS-CoV infection in bats indicating that bats are the reservoir host of several CoVs having the ability to cause severe respiratory syndromes (Li [@CR14], Lau [@CR11]). Nasopharyngeal, anal swabs and blood collected from 127 bats, 60 rodents and 20 monkeys at HKSAR region between 2004 and 2005 and subsequent isolation of CoVs revealed that 39% of Chinese horse shoe bats possess CoVs similar to SARS-CoVs. The genome analysis of the CoVs reveled the striking similarity of bat SARS-CoVs with that of human and civet SARS-CoVs (Lau [@CR11]). Whole genome sequence analysis of two novel CoVs (RsSHC014 and Rs3367) isolated from Chinese horse shoe bats of *Rhinolophidae* family were closely related to the SARS-CoV specially with respect to the receptor binding domain (RBD) of the viral spike protein, and that CoVs of Chinese horse shoe bats can directly be transmitted to humans without any intermediate host was recognized (Ge [@CR6]). Identification and characterization of CoVs circulating in Chinese horse shoe bats possessed a severe threat to human population as evident from data and metagenomics study results obtained during the past 5 years (Ge [@CR6], Menachery [@CR17], He [@CR9]).

Table 1Reported coronaviral infection in humansCoVGenusYear of identificationPrimary ReceptorSpecies of origin/Natural hostRefHCoV-OC43Betacoronavirus1890 (probable)9-*O*-acetylated sialic acidRodentCui [@CR5]HCoV-229EAlphacoronavirus1965human aminopeptidase NBatCui [@CR5]SARS-CoVBetacoronavirus2003Angiotensin-converting-enzyme 2BatCui [@CR5]HCoV-NL63Alphacoronavirus2004Angiotensin-converting-enzyme 2BatCui [@CR5]HCoV-HKU1Betacoronavirus20059-*O*-acetylated sialic acidRodentCui [@CR5]MERS-CoVBetacoronavirus2012Dipeptidyl-peptidase 4BatCui [@CR5]SARS-CoV-2Betacoronavirus2019Angiotensin-converting-enzyme 2BatZhou [@CR29]

SARS coronaviral infections and pathogenicity in experimental animals {#Sec3}
=====================================================================

The threats from CoVs had urged the scientific community to search for therapeutics, vaccines and diagnostics from the very initial stage resulting in experimental infection of animals with human or field isolates of the virus. The novelty of CoVs and differences in receptor binding domains of viral spike protein across multiple species was elusive on several occasions. SARS-CoVs uses the ACE2 receptor for entry into cells. Sequence homology of both ACE2 receptor varies across species and hence exhibition of human like symptoms in animals is not always observable in case of infection. Non-human primates (NHP) like African green monkeys (AGM), rhesus monkeys and cynomolgus monkeys when inoculated with of SARS-CoVs failed to show clinical signs of infection in all the species (only 1 out of 4 AGM showed high rectal temperature). Viral replication was evident in all the three species of monkeys and the replication was found to be higher in AGMs as compared to rhesus and cynomolgus. The early infection of broncho-tracheal epithelial cells and type 1 pneumocytes were also evident and consistent with observations in human SARS-CoV infection (McAuliffe [@CR15]). Common marmosets infected with SARS-CoV showed mild clinical signs and symptoms of respiratory illness. Non-hemorrhagic diarrhea was observed in 7 out of 12 infected animals. Viral antigens could be detected in alveolar cells and type 1 pneumocytes along with multiple tissues indicating human like tissue distribution and viral multiplication of SARS-CoV (Greenough [@CR8]). Cats and ferrets when inoculated with SARS-CoV did not show any clinical symptoms of illness although viral RNA could be detected in lungs, tracheobronchial lymph nodes and heart depicting asymptomatic illness (van den Brand [@CR25]). Pigs and chickens were also asymptomatic after inoculation with human isolates although viral RNA could be detected in spleen in pigs and in blood, respiratory tract, kidneys of chicken (Weingartl [@CR26]). Mice infected with SARS-CoV showed clinical signs of illness replicable of human like symptoms but young mice but do not show any clinical signs of illness, although virus multiplies in their respiratory tract (Roberts [@CR19]; Subbarao [@CR22]). In a recent study, mice inoculated with an emerging strain of CoV WIV1-MA15, a bat origin novel CoV showed no symptoms or lethality of infection (Menachery [@CR18]). Golden hamsters inoculated with a SARS-CoV strain shows no clinical signs of disease although viral RNA could be detected in respiratory tract (Roberts [@CR20]). The susceptibility, replication and pathogenicity is detailed in Table [2](#Tab2){ref-type="table"}.

Table 2Susceptibility, symptoms, viral replication and pathology in laboratory animals infected with SARS-CoVAnimal Species/StrainSusceptibility and SymptomsViral replication/distribution in organsHistopathological changesRefAfrican Green Monkeys (AGM),Rhesus Monkeys (RM),Cynomolgus Monkeys (CM)(infected with 10^6^ TCID50 of SARS-CoV strain)▪ No clinical signs of respiratory illness or fever in AGM, RM, CM (only 1/4 AGM monkey had 105^o^F rectal temperature on day 5)▪ Primary infection protected from reinfection in AGM▪ Viral replication observed in upper and lower respiratory tract of all the three species of monkeys▪ Absence of virus in plasma, urine and fecal samples, viral RNA detected in fecal samples of AGM between day 8 and day 20 Post Inoculation(PI)▪ Decrease of hemoglobin concentration and hematocrit in AGM but not in RM or CM▪ Elevation of liver enzymes in AGM but not in RM or CM▪ Focal interstitial mononuclear infiltration in lungs, edema, infiltration of macrophages in AGMMcAuliffe [@CR15]Common Marmosets(infection with 10^6^ TCID50 of SARS-CoV Urbani strain)▪ Mild symptoms of respiratory illness▪ Significant increase in body temperature on day 4 and 7 PI▪ Non-hemorrhagic diarrhea in 7/12 animals▪ Viral RNA detected in lungs, tracheobronchial lymph nodes and heart▪ No viral RNA detected in intestine and liver▪ Multifocal atelectasis in lungs, tracheobronchial lymphadenopathy in 2/12 animals▪ Pneumonitis and edema in lungs▪ No gross pathological changes in heart, liver, kidneys, spleen or GI tract▪ Multifocal hepatitis▪ Mild diffuse colitis in 8/12 animals▪ No renal pathology evident in any animalsGreenough, [@CR8]Cats(infected with 10^6^ TCID50 of SARS-CoV strain)▪ No clinical signs of illness▪ Primary infected organ being the respiratory tract, lungs and intestine▪ Multifocal pulmonary consolidation in 4/4 cats▪ Lung histology reveals multifocal necrosis, type II pneumocyte hyperplasia, karyorrhexis, neutrophil infiltration in alveolar septavan den Brand [@CR25]Ferrets(infected with 10^6^ TCID50 of SARS-CoV strain)▪ 4/4 animals lethargic 2-day PI▪ 1/4 animal died on 4-day PI▪ Primary infected organ being the respiratory tract and lungs▪ Multifocal pulmonary consolidation in 4/4 ferret▪ Exudative diffusive alveolar damage, infiltration of neutrophils and macrophages in alveolar septa, hypertrophy and hyperplasia in type II pneumocytes, lymphoid aggregation around pulmonary blood vessels▪ Diffused hepatic lipidosis and congestion▪ Lymphoid hyperplasia in trachea bronchial lymph nodes and spleen▪ Enlarged lymph node and friable livervan den Brand [@CR25]Hamsters(infected with 10^3^/10^5^ TCID50 of SARS-CoV strain)▪ No weight loss or clinical signs of disease▪ Animals recovering from primary infection protected by secondary challenge on day 28▪ Respiratory tract and lungs▪ Virus not distributed in liver, spleen, kidneys, GI tract or other organs▪ Blebbing and swelling of luminal cytoplasm in bronchi, trachea and nasal tract▪ Mono nuclear cell infiltrates in submucosal epithelium of bronchioles and nasal tract▪ Multifocal areas of consolidation round the bronchioles▪ Damages in nasal passage healed on 5 day PI and viral antigen not detectable in lungs 7 days PIRoberts [@CR20]BalbC mice(12-14-month old infected with 10^5^ TCID50 SARS-CoV urbani strain)▪ Clinical signs of disease observed like weight loss, ruffled fur, dehydration upto 7-day PI▪ Virus detected in upper respiratory tract, lungs and liver▪ Virus not detected in whole blood▪ Airway epithelial necrosis, multifocal and interstitial lymphohystiocytic infiltration and proteinaceous deposition around the alveolar walls, intra-alveolar edema evident from IHC▪ Levels of IFNα, IFNγ, TFNα elevated 2--3 day PI in infected lungsRoberts [@CR19]10 weeks old BalbC mice(infected with 10^4^ PFU of WIV1-MA15/SARS-CoV-MA15 strains of SARS-CoV)▪ Rapid weight loss and death in SARS-CoV-MA15▪ WIV1-MA15 resulted in no weight loss or lethality▪ Viral replication reported in lungs▪ Not reportedSubbarao [@CR22]C57BL6 mice(infected with 10^4^ TCID50 SARS-CoV urbani strain )▪ No clinical signs of disease, slow increase of body weight, no mortality▪ Virus replicates in lungs and cleared by day-9 PI▪ Beige, CD1^−/−^, RAG1^−/−^ mice of C57BL6 background cleared the virus in a normal way▪ Viral RNA detected in lung, liver, spleen, heart and brain but not in kidneys▪ Viral RNA detected in epithelial lining of bronchi and terminal bronchioles but not in alveoli of lungs▪ Less leukocyte infiltration in lungs of infected mice; no significant change in BALF of infected and mock infected mice▪ Focal necrosis, alveolar damage, bronchiolar lining disintegration, mild endothelial swelling in lungs▪ Significant increase in mRNA transcripts in infected mice as compared to mock infected mice▪ Infected mice shows normal liver and kidney functionsGlass [@CR7]Pigs(infected with 2\*10^6^ PFU of SARS-CoV human isolate)▪ No clinical signs of disease▪ Viral RNA detected only in spleen▪ Not reportedWeingartl [@CR26]Chickens(infected with 10^6^ PFU of SARS-CoV human isolate)▪ No clinical signs of disease▪ Viral RNA detected in blood, traches, lungs and kidney but not in spleen, liver and jejunum▪ Not reportedWeingartl [@CR26]

SARS-CoV-2 infection and pathogenicity in experimental animals: recent findings {#Sec4}
===============================================================================

Recent studies indicate that ferrets are susceptible to SARS-CoV-2 infection with viral isolates from environmental and patient samples. The virus could be replicated in the upper respiratory tract and the virulence was restricted to mild disease without death. SARS-CoV-2 could bind to epithelial cells and type II pneumocytes of the lungs in ferrets but could not replicate within the lungs indicating that infection was restricted only to upper respiratory tract in ferrets (Shi [@CR21]). Identical studies conducted in sub adult cats revealed that droplet transmission of SARS-CoV-2 can occur in cats and they are susceptible for infection however, infection is limited to upper respiratory tract in cats. Interestingly juvenile cats when inoculated with SARS-CoV-2 resulted in death or severe morbidity and histopathological lesions were observed in both upper and lower respiratory tract (Shi [@CR21]). Dogs are mildly susceptible to SARS-CoV-2 infection whereas similar studies conducted on pigs, ducks and chickens revealed no susceptibility of these species to SARS-CoV-2 infection (Shi [@CR21]). Syrian hamsters when inoculated with SARS-CoV-2 showed similarity in disease pathogenesis, progression and transmissibility as observed in human infections. Severe infection of both upper and lower respiratory tracts, histopathological findings, cytokine and chemokine levels and changes in extra pulmonary organs were also evident (Chan [@CR4]). Rhesus monkeys infected with SARS-CoV-2 showed viral presence in respiratory tract and gut (Bao [@CR2]). The findings are very necessary and important in the race for developing a therapeutic drug or vaccines against SARS-CoV-2. The susceptibility, replication and pathogenicity is detailed in Table [3](#Tab3){ref-type="table"}.

Table 3Susceptibility, symptoms, viral replication and pathology in laboratory animals infected with SARS-CoV-2Animal Species/StrainSusceptibility and SymptomsViral replication/distribution in organsHistopathological changesRefRhesus Monkeys (infected with 10^6^ TCID50 of SARS-CoV-2 strain)▪ Transient clinical signs of disease like loss of body weight, hunched posture, reduced appetite and increased respiration rate▪ No changes in body temperature▪ Viral RNA detected in nasal, pharyngeal and rectal swabs▪ Viral replication evident in lungs and extra-pulmonary organs like heart, spinal cord, gut, skeletal muscle and urinary bladder▪ Moderate interstitial pneumonia, macrophage accumulation in alveoli, thickened alveolar septa, alveolar epithelial degradation,▪ bilateral ground glass opacification of lungsBao [@CR2]Cats(infected with 10^5^ PFU of CTan-H strain)▪ Respiratory droplet transmission from infected cat to non-infected cat▪ Viral RNA detected in trachea, lungs, small intestine, tonsils, soft palate and nasal turbinate at 3 day PI in sub-adult cats▪ Viral RNA detected in both upper respiratory tract and lungs in juvenile cats▪ Respiratory droplet transmission from infected cat to non-infected cat▪ Lesions observed in upper and lower respiratory tract in juvenile catsShi [@CR21]Ferrets(infected with 10^5^ PFU of F13-E strain and CTan-H strain of SARS-CoV-2)▪ 1/3 ferret developed loss of appetite and fever▪ Viral RNA detected in tonsils, nasal turbinate and soft palate of all ferrets and not in any other organ▪ Viral RNA detected in nasal washes and rectal swab▪ Vasculitis, increased type II pneumocytes, neutrophilic infiltration in alveolar lumen and septa▪ Lungs showing mild peribronchitisShi [@CR21]Beagle Dogs(infected with 10^5^ PFU of CTan-H strain)▪ No symptoms reported▪ Viral RNA detected in rectal swabs▪ Viral RNA not detected in any organ or tissue▪ Not reportedShi [@CR21]Pigs(infected with 10^5^ PFU of CTan-H strain)▪ No symptoms reported▪ Viral RNA not detected in any nasal/rectal swabs or any organs▪ Not reportedShi [@CR21]Ducks(infected with 10^5^ PFU of CTan-H strain)▪ No symptoms reported▪ Viral RNA not detected in any nasal/rectal swabs or any organs▪ Not reportedShi [@CR21]Chickens(infected with 10^5^ PFU of CTan-H strain)▪ No symptoms reported▪ Viral RNA not detected in any nasal/rectal swabs or any organs▪ Not reportedShi [@CR21]Hamsters(infected with 10^5^ PFU of patient isolate of SARS-CoV-2)▪ Animals exhibit disease symptoms▪ Virus transmitted from infected to close contact animals▪ High viral load in nasal turbinate, trachea and lungs detected in culture▪ Viral RNA detected in multiple extra-pulmonary tissues but viral N protein detected only in intestine▪ Upregulation of cytokines and chemokines in lungs▪ Mono-nuclear cell infiltration, focal cilia loss, epithelial cellular swelling observed in trachea▪ Focal inflammation, pleural invaginations, fluid exudate, diffused alveolar destruction, hemorrhagic alveolar collapse observed in lungs▪ Epithelial cell necrosis, damaged intestinal villi, increased mono-nuclear cellular infiltration observed in intestine▪ Reduction in spleen size, mild focal myocardial degeneration of heartChan [@CR4]

Host pathogen interactions of SARS-CoVs in experimental animals with respect to ACE2 RBD {#Sec5}
========================================================================================

SARS-CoVs are assumed to have been originated through natural sources from other mammalian species (most likely from bat), it failed to mimic human clinical disease in animals and thereby limiting in depth of knowledge on infection process and possible modes of prevention and cure of this infection. The virus only exhibited transient viremia and milder symptoms in many of the model species while in some cases experimental infection ended without any clinical symptom or histopathological changes. In this context, high affinity virus receptor interaction might be one of the crucial factors that determines virulence of the pathogen in the host. This can be justified by the fact that experimental infection of hACE2 (functional receptor of SARS-CoV) expressing transgenic mice show clinical manifestations similar to human infection in comparison to the parental wild type mice (Tseng [@CR24]). Likewise, murine 3T3 cells expressing human ACE2 were more susceptible to SARS-CoV infection as compared to murine ACE2 (Li [@CR12]). Host cellular invasion of SARS-CoV is mediated through interactions among distinct receptor-binding domains (RBD) on the SARS-CoV spike (S) protein and its functional receptor ACE2 wherein S protein binding domains are localized at 30--41 amino acid (aa) and 82--84 amino acid of ACE2 (Li [@CR13]). Therefore, the likelihood that sequence homology at S protein binding domains is the key determinant on susceptibility and clinical manifestation of SARS-CoV in animals. In line with this hypothesis, analysis of human ACE2 protein sequence with other potential host (experimental and reservoir) animals revealed more homology in bat vs. human and rhesus monkey than bat vs. other mammals at 30--41 aa region (Fig. [1](#Fig1){ref-type="fig"}). However, human and monkey ACE2 showed relatively less homology towards bat ACE2 at 82--84 aa region than cat, dog, ferret, marmoset, civet and raccoon. In both the S protein binding regions of ACE2, mouse and rat displayed distant homology for bat ACE2 than other species. Thus, it is likely that higher homology at binding domains in ACE2 receptor enabled SARS-CoVs for cross species infection from reservoir host to human during close proximity of human and bat in food markets in China. Similarly, the distant homology at S protein binding domains in mouse and rat ACE2 with bat and human ACE receptor possibly explains limited success in developing representative animal models for in depth study of SARS-CoV-2 infection. However, other host factors such as age, virome, host genetics, immune response pattern, previous and concomitant infections etc. may also play important role in mild or lack of clinical symptoms in animals (Sumbria [@CR23]). Likewise, influence of other receptors like CD209L (Jeffers [@CR10]) and Aminopeptidase N (APN) (Wentworth [@CR27]) in efficiency of infection and replication of SARS-CoV in other host species cannot be excluded.

Fig. 1Alignment of ACE2 amino acid sequences of different mammals. Analysis was performed by Clustal Omega programme using SnapGene software. Gene bank accession number of ACE2 proteins for indicated species are- *H. sapiens*, AB193260; *R. leschenaultia*, AB299376; *M. mulatta*, FJ170076; *C. jacchus*, XM_008988993.1; *P. larvata*, AY881174; *N. procyonoides*, EU024940; *Mustela putorius furo*, AB208708; *F. catus*, AB211997.1; *Canis lupus familiaris*, NM_001165260; *R. norvegicus*, AY881244; *M. musculus*, AK141604; *B. taurus*, NM_001024502.4.; *B. bubalis*, XM_006041540.2; *C. hircus*, XM_005701072; *O. aries*, XP_011961657

One of the conventional way of developing animal models of viral infection is adaptation of the pathogen in laboratory animal by serial passaging. This will eventually enable the virus to gain virulence in the animal host and thereby represent physiological responses of regular infection. Serial passaging of wild type virus in unnatural host also reduces its virulence towards normal host and is the traditional method of development of live attenuated vaccine for original host. However, adaptation of human virus in different host species may also impose potential risk of evolution of new viral strain which in turn may cause new epidemic.

hACE2 transgenic mice in SARS-CoV and SARS-CoV-2 experimentation {#Sec6}
================================================================

The SARS-CoV and SARS-CoV-2 uses the ACE2 receptor for cellular entry hence transgenic mice bearing *h*ACE2 receptor is reported to be a good model for SARS-CoV multiplication. K18-*h*ACE2 mice when inoculated with SARS-CoV isolates showed signs and symptoms of severe infections. In K18-*h*ACE2 mice CNS had been a major target for SARS-CoV infection which also mimics in SARS-CoV-2 infection as there were attempts to isolate this virus from cerebral microcirculations, cerebrospinal fluids and neuronal tissues (McCray [@CR16]; Bao [@CR3]). A transgenic mice expressing hACE2 (AC70) showed similar types of infection like clinical signs of illness, weight loss, loss of breath and mortality and infection spread to multiple tissues including the brain (Tseng [@CR24]). *h*ACE2 mice infected with SARS-CoV-2 strain resulted in weight loss but no signs of respiratory illness were reported. Viral antigens could be detected in lungs and intestine but not in other major organs like brain, kidneys and liver (Bao [@CR3]). The susceptibility, replication and pathogenicity of SARS and SARS-CoV-2 is detailed in Table [4](#Tab4){ref-type="table"}.

Table 4Susceptibility, symptoms, viral replication and pathology in hACE2 transgenic mice infected with SARS-CoV and SARS-CoV-2Animal Species/StrainSusceptibility and SymptomsViral replication/distribution in organsHistopathological changesRefK18-hACE2 mice(infected with 2.3 × 10^4^ PFU of SARS-CoV strain)▪ Shows severe signs of disease like weight loss, lethargy and labored breathing▪ SARS-CoV not transmitted from infected to non-infected mice▪ viral titers detected in lungs, brain▪ Virus not detected in liver, small intestine and kidneys▪ Detection of viral antigen in cerebrum, cerebellum, thalamus, brainstem, olfactory balb▪ Perivascular and peribronchiolar inflammation▪ Epithelial cell sloughing, hemorrhage, congestion in alveolar septa▪ Intense neutrophilic infiltration, necrotizing bronchopnemmonia▪ Upregulation of cytokines and chemokines in lungs and brainMcCray [@CR16]*h*ACE2-AC70 mice(infected with 2 × 10^5^/10^3^ TCID50 of SARS-CoV strain)▪ Symptoms of weight loss, lethargy, ruffled fur, shallow breathing▪ 100% Mortality 8-day PI▪ Viral replication detected in lungs and brain, low level of viremia detected in blood▪ Virus could be detected in bowels, nasal washes and liver but not in throat swabs▪ Virus not detected in heart, kidneys, urine, spleen▪ Moderate interstitial pneumonitis, alveolar wall thickening, presence of cellular debris and macrophages in alveolar sacks and airways▪ Cytoplasmic swelling, blebbing in bronchoepithelial cells▪ Viral antigen detected in ganglion cells and vascular smooth muscles of lungs and blood vessels, glial cells of CNS▪ Elevated levels of cytokines and chemokines in lungsTseng [@CR24]HFH4-*h*ACE2 mice(infected with 10^5^ PFU of SARS-CoV urbani strain)▪ Rapid weight loss, and death between day 4--5▪ Viral replication in brain, lungs▪ Not reportedMenachery 2016*h*ACE2-mice(infected with 10^5^ TCID50 of SARS-CoV-2 strain)▪ Slight weight loss and bristled fur, no other clinical signs reported▪ Viral RNA detectable in lungs, intestine▪ Virus could be isolated from lungs in Vero E6 cell line▪ Viral antigens not detected in kidneys, liver, spleen, myocardium, testis or brain▪ Dark reddish-purple areas and nodules found in lungs▪ Moderate interstitial pneumonia, thickening of alveolar septa, infiltration of inflammatory cells in alveolar cavities, high infiltration of macrophages, neutrophils and lymphocytes in perivascular region▪ Swollen, degenerated Broncho epithelial cellsBao [@CR3]

Discussions {#Sec7}
===========

The genome sequence analysis of SARS-CoV-2 reveals that it shares a sequence identity of 79.6% to SARS-CoV and has 96% identity level of its genome with a novel bat CoV RatG13 indicating its bat origin. The receptor binding spike protein of SARS-CoV-2 had less than 75% sequence homology with previously described all SARS related CoVs but the virus uses ACE2 receptor for cellular entry like other SARS-CoVs and it did not show any affinity for other cellular binding domains like DPP4 and aminopeptidase N. Some SARS-CoV-2 genes shows less than 80% sequence identity with SARS-CoV. There are differences in the spike protein gene between SARS-CoV-2 and SARS-CoV in four out of five key residues of receptor binding motif and three short insertions in N-terminal domain of S-gene (Zhou [@CR29]).

Non-human primates showed no clinical signs of respiratory illness when infected with SARS-CoV strain, however in infection with SARS-CoV-2 strain, initial clinical signs like loss of body weight, hunched posture, loss of appetite are evident. Viral replication in monkeys is also evident in respiratory organs rendering histopathological changes in lungs but extra-pulmonary replication is more evident and pronounced in SARS-CoV-2 infection as compared to SARS-CoV indicating more virulence and pathogenicity. Clinical symptoms and pathological manifestations were observed in common marmosets in SARS-CoV infection but data pertaining to SARS-CoV-2 infection in marmosets is currently not reported.

Higher virulence and fatality of juvenile cats infected with SARS-CoV-2 is reported. Cats are one of the most popular companion animals of humans and are highly vulnerable in SARS-CoV-2 pandemic. There is also a possibility of reverse transmission of virus from infected cats to humans although sufficient data is not available to establish this fact. Ferrets infected with both the viruses show similarities of clinical illness, but infection in ferrets by SARS-CoV-2 is restricted to upper respiratory tract while viral RNA could also be detected in lungs of ferrets in SARS-CoV infection. Hamsters challenged with SARS-CoV strain showed no clinical signs of illness and weight loss but infection with SARS-CoV-2 results in clinical signs of disease. Pigs and chickens are asymptomatic in infections with both SARS-CoV and SARS-CoV-2.

It is also quite notable that the SARS-CoV-2 patients with associated heart disease, diabetes and other systemic disease are more susceptible to fatality. It may be because of multiple disruptions in the system as a result of neurological invasion of SARS-CoV-2 (Baig [@CR1]). Spread of SARS-CoV to multiple organs including brain was demonstrated in K18-hACE2 and hACE2 (AC70) mice from actual site of infection i.e. lungs but interestingly hACE2 transgenic mice infected with SARS-CoV-2 show no presence of viral antigens in brain. SARS-CoV-2 is shown to be highly virulent than SARS-CoV infection resulting in severe signs of respiratory illness and mortality, however, mild symptoms are observed in hACE2 transgenic mice while infected with SARS-CoV-2.

It is quite evident from current knowledge that virulence in animal models with SARS-CoV-2 infection is higher in some of the species as compared to SARS-CoV infection but hACE2 mice are more permissive to infection with SARS-CoV as compared to SARS-CoV-2. The background of strains, age, sex etc. must also be evaluated in species as viral invasion and replication does not solely depend on the entry of virus within the host but host adaptability and immune status also. The testing of new chemical entities, drug repurposing and vaccine evaluations count a good preclinical animal experimentation data, it is high time that research should be directed in searching for reliable and reproducible animal models for emerging coronaviral infections.
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